Clinical Trial Update: Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 long-term safety trial of etrolizumab in moderate to severe ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Etrolizumab (etrolizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED